Determination of dihydromyricetin in rat plasma by LC–MS/MS and its application to a pharmacokinetic study

Tong, Qingyi; Hou, Xiao-Long; Fang, Jianguo; Wang, Wenqing; Xiong, Wei; Liu, Xu; Xie, Xue-Jia; Shi, Chunyu

doi:10.1016/j.jpba.2015.06.030

Cited by 58 publications

(51 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The results of this study indicate that DHM may influence the in vitro metabolism of drugs that are substrates of CYP3A4, CYP2E1 and CYP2D6. Some research articles Tong et al 2015) have investigated the pharmacokinetic profiles of DHM in rats, and the results indicated that the C max values of DHM in rats reached 1.7 lg/mL after oral administration of a dose of 1564.8 mg/kg of Rattan Tea decoction. Therefore, the rat plasma concentrations of DHM was similar to the Ki and IC 50 values of DHM determined in this study, and herb-drug interaction might occur if DHM were co-administered with the substrates of the CYP3A4, CYP2E1 and CYP2D6.…”

Section: Discussionmentioning

confidence: 99%

In vitro inhibitory effects of dihydromyricetin on human liver cytochrome P450 enzymes

Liu

Sun

Rui

et al. 2017

Pharmaceutical Biology

View full text Add to dashboard Cite

Context: Dihydromyricetin (DHM) is the most abundant and active flavonoid component isolated from Ampelopsis grossedentata (Hand-Mazz) W.T. Wang (Vitaceae) and it possesses numerous pharmacological activities. However, whether DHM affects the activity of human liver cytochrome P450 (CYP) enzymes remains unclear. Materials and methods: The inhibitory effects of DHM on eight human liver CYP isoforms (i.e., 1A2, 3A4, 2A6, 2E1, 2D6, 2C9, 2C19 and 2C8) were investigated in vitro using human liver microsomes (HLMs). Results:The results showed that DHM could inhibit the activity of CYP3A4, CYP2E1 and CYP2D6, with IC 50 values of 14.75, 25.74 and 22.69 lM, respectively, but that other CYP isoforms were not affected. Enzyme kinetic studies showed that DHM was not only a non-competitive inhibitor of CYP3A4 but also a competitive inhibitor of CYP2E1 and CYP2D6, with Ki values of 6.06, 9.24 and 10.52 lM, respectively. In addition, DHM is a time-dependent inhibitor for CYP3A4 with K I /K inact value of 12.17/0.057 min À1 lM À1 . Discussion and conclusion: The in vitro studies of DHM with CYP isoforms indicate that DHM has the potential to cause pharmacokinetic drug interactions with other co-administered drugs metabolized by CYP3A4, CYP2E1 and CYP2D6. Further clinical studies are needed to evaluate the significance of this interaction. ARTICLE HISTORY

show abstract

Section: Discussionmentioning

confidence: 99%

In vitro inhibitory effects of dihydromyricetin on human liver cytochrome P450 enzymes

Liu

Sun

Rui

et al. 2017

Pharmaceutical Biology

View full text Add to dashboard Cite

show abstract

“…Finally, 200 μL supernatant was collected for HPLC‐MS/MS analysis. The HPLC‐MS/MS method was in accordance with our previous study (Tong et al., ).…”

Section: Methodsmentioning

confidence: 99%

“…Previously, the pharmacokinetics, tissue distribution, excretion, and metabolic profile of DMY were studied after oral administration (100 mg/kg) in rats (Fan et al., ; Tong et al., ). DMY could be rarely absorbed in the gastrointestinal tract (GI) and showed poor oral bioavailability (Tong et al., ). Although DMY could be distributed widely in different organs such as liver, kidney, lung, brain, and heart, it was predominantly distributed in the GI.…”

Section: Introductionmentioning

confidence: 99%

Interactions of Dihydromyricetin, a Flavonoid from Vine Tea (Ampelopsis grossedentata) with Gut Microbiota

Fan

Zhao

Tong

et al. 2018

Journal of Food Science

Self Cite

View full text Add to dashboard Cite

show abstract

“…Dihydromyricetin (DHM) is the most abundant and bioactive flavonoid component of Ampelopsis grossedentata . Over hundreds of years, DHM has been proven to have numerous pharmacological activities, including antioxidant, anti-inflammation, antihypertension, anticancer, hepatoprotection against alcohol intoxication, and antifatigue activities [5]. DHM can prevent adriamycin-induced cardiotoxicity by protecting myocardial cells from apoptosis and attenuate angiotensin II-induced rat cardiomyocyte hypertrophy in an NO-dependent manner [6, 7].…”

Section: Introductionmentioning

confidence: 99%

Dihydromyricetin Protects against Diabetic Cardiomyopathy in Streptozotocin-Induced Diabetic Mice

Lin

Luo

et al. 2017

BioMed Research International

View full text Add to dashboard Cite

Diabetic cardiomyopathy (DCM) is an important cause of heart failure in diabetic patients. The present study sought to explore the potential effects of dihydromyricetin (DHM) on DCM and its possible mechanism. A diabetic model was induced by intraperitoneal injection of streptozotocin (STZ) in C57BL/6J mice. Two weeks after the STZ injection, mice were randomly allocated into the following 4 groups for treatment: the control group (CON), the control treated with DHM group (CON + DHM), the diabetes group (DM), and the diabetes treated with DHM group (DM + DHM). DHM was dissolved in distilled water and administered daily by gavage. For 14 weeks, the CON + DHM group and DM + DHM group were given a dose of 100 mg/kg/day DHM (Sigma-Aldrich), while the CON and DM groups were intragastrically given equivalent volumes of distilled water. Assessments and comparisons were made among the groups based on cardiac function and structural changes, inflammation factors, markers of oxidative stress, mitochondria function, apoptosis, and autophagy. The DHM treatment normalized body weight, preserved cardiac function, attenuated oxidative stress (MDA, SOD, and GSH-Px), reduced the levels of inflammation factors (IL-6, TNF-α), alleviated pathological changes, improved mitochondrial function (ATP content, CS activity, and complex Ι/ΙΙ/ΙΙΙ/ΙV/V activities), inhibited cardiac apoptosis, and restored autophagy in diabetic mice. DHM may have a great therapeutic potential in the treatment of DCM.

show abstract

Determination of dihydromyricetin in rat plasma by LC–MS/MS and its application to a pharmacokinetic study

Cited by 58 publications

References 15 publications

In vitro inhibitory effects of dihydromyricetin on human liver cytochrome P450 enzymes

In vitro inhibitory effects of dihydromyricetin on human liver cytochrome P450 enzymes

Interactions of Dihydromyricetin, a Flavonoid from Vine Tea (Ampelopsis grossedentata) with Gut Microbiota

Dihydromyricetin Protects against Diabetic Cardiomyopathy in Streptozotocin-Induced Diabetic Mice

Contact Info

Product

Resources

About